Hyperperfusion of bilateral amygdala in patients with chronic migraine: an arterial spin-labeled magnetic resonance imaging study.

"Declarations Ethics approval and consent to participateAll participants received a complete description of the study and granted written informed consent. This study had been registry on Clinical Trial (NCT05334927) and ethical approval was granted by Beijing Tiantan Hospital, Capital Medical University (no. KY2022-044). Consent for publicationAll authors have agreed to the current submission. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by National Natural Science Foundation of China (Grant No. 62271061, 32170752, 91849104, and 31770800), Beijing Municipal Natural Science Foundation (Grant No. 7212028), and the National Natural Science Foundation of Beijing (Z200024)."

"The present study was a substudy of the ongoing China HeadAche DIsorders RegiStry Study (CHAIRS, trial registration number: NCT05334927, https://www.clinicaltrials.gov). From October 2020 to November 2022, 28 healthy controls (HCs) and 94 patients diagnosed with EM (n = 30) or CM (n = 64) were consecutively enrolled in the Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University. This work was approved by the Institutional Review Board (KY2022-044) of Beijing Tiantan Hospital, Capital Medical University. All participants provided written informed consent prior to study enrollment. The inclusion criteria for EM and CM groups were (1) fulfillment of the criteria for EM or CM, according to the 3rd edition of the International Classification of Headache Disorders (ICHD-3) [], (2) age 20 to 65 years, (3) all patients with migraine without aura. The exclusion criteria for EM and CM groups were (1) presence of another type of primary headache, (2) MRI claustrophobia or contraindications, (3) poor image quality, and (4) brain damage or other neurological diseases (e.g., epilepsy, stroke, and/or physical disease) that could affect the results of the study. The inclusion criteria for HCs were (1) ability to undergo MRI scanning (i.e., no claustrophobia and no metal in the body), (2) no neurological or other major systemic diseases, and (3) age and sex matched to patients in the EM and CM groups. The exclusion criteria for HCs were (1) pregnancy or breastfeeding, (2) MRI contraindications, and (3) poor MRI data quality. Declarations: Ethics approval and consent to participateAll participants received a complete description of the study and granted written informed consent. This study had been registry on Clinical Trial (NCT05334927) and ethical approval was granted by Beijing Tiantan Hospital, Capital Medical University (no. KY2022-044).: Consent for publicationAll authors have agreed to the current submission.: Competing interestsThe authors declare no competing interests. Ethics approval and consent to participate: All participants received a complete description of the study and granted written informed consent. This study had been registry on Clinical Trial (NCT05334927) and ethical approval was granted by Beijing Tiantan Hospital, Capital Medical University (no. KY2022-044)."